 |
|
Presymptomatic Neuromuscular Disorders Disclosed Following Statin Treatment
Georgios Tsivgoulis, MD;
Konstantinos Spengos, MD;
Nikolaos Karandreas, MD;
Marios Panas, MD;
Athina Kladi, MS;
Panagiota Manta, MD
Arch Intern Med. 2006;166:1519-1524.
It is well recognized that statins affect muscular tissue adversely and that their use is associated with clinically important myositis, rhabdomyolysis, mild elevation of serum creatine kinase (CK) levels, myalgias, muscle weakness, muscle cramps, and persistent myalgias or serum CK level elevations after statin treatment is discontinued. The association between statins and the disclosure of presymptomatic metabolic myopathy is another underrated phenomenon related to statin therapy that was recently recognized in rare cases. The purpose of this report is to provide additional support for this association and to report other neuromuscular disorders that have also been seen following statin intake. The present case series illustrates that statins may act as unmasking agents in asymptomatic patients with a latent neuromuscular disorder. Thus, it may be postulated that statin intake may be a sufficient insult to precipitate neuromuscular symptoms and substantially increase muscle enzymes in presymptomatic patients with an abnormal neuromuscular substrate. In conclusion, muscular symptoms or increased serum CK levels persisting after statin treatment discontinuation should alert the clinician to pursue further diagnostic evaluations for the detection of potential underlying neuromuscular diseases.
Author Affiliations: Department of Neurology, University of Athens Medical School, Eginition Hospital, Athens, Greece.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study
Sailler et al.
Ann Rheum Dis 2008;67:614-619.
ABSTRACT
| FULL TEXT
Statin Therapy and Underlying Neuromuscular Disorders
JWatch Neurology 2006;2006:3-3.
FULL TEXT
|
